Search results
Results From The WOW.Com Content Network
para-Methoxyamphetamine (PMA), also known as 4-methoxyamphetamine (4-MA), is a designer drug of the amphetamine class with serotonergic effects. [2] [3] [4] Unlike other similar drugs of this family, PMA does not produce stimulant, euphoriant, or entactogen effects, [5] and behaves more like an antidepressant in comparison, [6] though it does have some psychedelic properties.
para-Methoxymethamphetamine (PMMA), also known as 4-methoxy-N-methylamphetamine (4-MMA), is a serotonergic drug of the amphetamine family related to para-methoxyamphetamine (PMA). It is the 4- methoxy analogue of methamphetamine .
3-Methoxyamphetamine (3-MA), also known as meta-methoxyamphetamine (MMA), is a monoamine releasing agent (MRA) of the amphetamine family. [ 2 ] [ 3 ] [ 4 ] It is a positional isomer of para -methoxyamphetamine (PMA; 4-methoxyamphetamine).
Methoxyamphetamine may refer to: 2-Methoxyamphetamine (2-MA) ... 4-Methoxyamphetamine (4-MA) or para-methoxyamphetamine (PMA) See also. Dimethoxyamphetamine;
An assortment of several designer drugs. Designer drugs are structural or functional analogues of controlled substances that are designed to mimic the pharmacological effects of the parent drug while avoiding detection or classification as illegal.
4-Methylthioamphetamine (4-MTA), also known as para-methylthioamphetamine (MTA), is a designer drug of the substituted amphetamine class developed in the 1990s by a team led by David E. Nichols, an American pharmacologist and medical chemist, at Purdue University. It acts as a non-neurotoxic highly selective serotonin releasing agent (SSRA) in ...
But just 31 percent of the 7,745 doctors in those areas are certified to treat the legal limit of 100 patients. Even in Vermont, where the governor in 2014 signed several bills adding $6.8 million in additional funding for medication-assisted treatment programs, only 28 percent or just 60 doctors are certified at the 100-patient level.
[3] 3,4-DMA has been found to be a monoamine oxidase inhibitor (MAOI), with an IC 50 Tooltip half-maximal inhibitory concentration of 20,000 nM for monoamine oxidase A (MAO-A), whereas it was inactive at monoamine oxidase B (MAO-B) (IC 50 > 100,000 nM). [4] [5] 3,4-DMA produces 3-methoxy-4-hydroxyamphetamine (MHA) as its major metabolite in ...